NASDAQ:LGND
Ligand Pharmaceuticals Incorporated Stock News
$73.90
+1.58 (+2.18%)
At Close: May 03, 2024
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2021 Results - Earnings Call Transcript
02:57am, Friday, 18'th Feb 2022 Seeking AlphaLigand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2021 Results - Earnings Call Transcript
09:57pm, Thursday, 17'th Feb 2022
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2021 Results - Earnings Call Transcript
Ligand Pharmaceuticals Non-GAAP EPS of $1.80 beats by $0.43, revenue of $72.5M beats by
09:04pm, Thursday, 17'th Feb 2022 Seeking Alpha
Ligand Pharmaceuticals press release (LGND): Q4 Non-GAAP EPS of $1.80 beats by $0.43.Revenue of $72.5M (+3.6% Y/Y) beats by $7.41M.As of December 31, 2021, Ligand had cash,…
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
01:00pm, Thursday, 17'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March
Amylyx Pharma
Ligand Pharmaceuticals Q4 2021 Earnings Preview
10:35pm, Wednesday, 16'th Feb 2022 Seeking Alpha
Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q4 earnings on Thursday, Feb. 17, after market close.The consensus EPS estimate is $1.37 (-15.4% Y/Y)
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
02:11pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
01:32pm, Sunday, 13'th Feb 2022 Benzinga
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
02:15pm, Wednesday, 26'th Jan 2022 Zacks Investment Research
Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
03:07pm, Monday, 10'th Jan 2022 Zacks Investment Research
Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drug
Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
05:07am, Friday, 31'st Dec 2021 Seeking Alpha
Ligand's plans to spin off its OmniAb business have potential to unlock significant additional shareholder value. Click here to read more.
Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
12:07am, Friday, 31'st Dec 2021
Ligand's Q3 2021 struck a celebratory mood as its licensing partners' products advanced around the world. Ligand's breadth of partnerships assures that its long-term growth is secure.
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
03:04pm, Monday, 27'th Dec 2021 Zacks Investment Research
Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
11:28am, Monday, 27'th Dec 2021
Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.
Ligand Pharma, GSK expand existing license deal
09:40pm, Tuesday, 21'st Dec 2021 Seeking Alpha
Ligand (LGND) Moves 4.5% Higher: Will This Strength Last?
06:17am, Monday, 20'th Dec 2021 Zacks Investment Research
Ligand (LGND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
